Cartesian Therapeutics, Inc. — Director's Dealing 2021

Dec 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2021-12-09

Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-09	Common Stock	P	3748000	$3.06	Acquired	22902427	Indirect
2021-12-10	Common Stock	P	58681	$2.9897	Acquired	22961108	Indirect
2021-12-13	Common Stock	P	14592	$2.9805	Acquired	22975700	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	7293625	Direct
Common Stock	86418	Indirect

Footnotes

F1: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

F2: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.94 to $3.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.9698 to $3.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.